Form 4 Filing for Stephen A. Sherwin at Neurocrine Biosciences Inc.

This filing details a Form 4 executed by Stephen A. Sherwin, a director at Neurocrine Biosciences Inc., on May 29, 2026. The report covers transactions on May 27, 2026. Sherwin acquired 2,567 Restricted Stock Units (RSUs) with a transaction price of $0.00 per share. These RSUs represent the right to receive one share of the Issuer's common stock upon vesting. The RSUs will fully vest on May 27, 2027. Following this transaction, Sherwin directly owns 2,567 shares of common stock.